Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma

  • Authors:
    • Radka Vaclavikova
    • Jovana Klajic
    • Veronika Brynychova
    • Katerina Elsnerova
    • Grethe I.G. Alnaes
    • Jörg Tost
    • Vessela N. Kristensen
    • Lukas Rob
    • Roman Kodet
    • Petr Skapa
    • Marcela Mrhalova
    • Pavel Soucek
  • View Affiliations

  • Published online on: June 5, 2019     https://doi.org/10.3892/or.2019.7186
  • Pages: 763-774
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multidrug resistance to anticancer drugs, which is often associated with enhanced expression of the ATP‑binding cassette (ABC) transporter P‑glycoprotein (encoded by the ABCB1 gene) may limit the effects of cancer therapy. Epigenetic regulation of ABCB1 expression may thus have a clinical impact. A detailed assessment of ABCB1 promoter methylation is of importance for predicting therapy outcome and prognosis. Thus, validated methods for the analysis of ABCB1 promoter methylation are urgently required. In the present study, high‑resolution melting (HRM) analysis of the CpG island regions covering the distal promoter of the ABCB1 gene was developed and compared with pyrosequencing. In addition, the clinical effects of the methylation status of the ABCB1 promoter were analyzed in patients with breast and ovarian carcinoma prior and subsequent to chemotherapy treatment. HRM analysis of ABCB1 methylation correlated with the results of pyrosequencing (P=0.001) demonstrating its analytical validity and utility. Hypermethylation of the analyzed ABCB1 promoter region was significantly correlated with low levels of the ABCB1 transcript in tumors from a subset of patients with breast and ovarian carcinoma prior to chemotherapy but not following treatment. Finally, high ABCB1 transcript levels were observed in tumors of patients with short progression‑free survival prior to chemotherapy. Our data suggest the existence of functional epigenetic changes in the ABCB1 gene with prognostic value in tumor tissues of patients with breast and ovarian carcinoma. The clinical importance of such changes should be further evaluated.

References

1 

Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI

2 

Leonessa F and Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 10:43–73. 2003. View Article : Google Scholar : PubMed/NCBI

3 

Ling V: Multidrug resistance: Molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 40 (Suppl):S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI

4 

Sakaeda T, Nakamura T and Okumura K: Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem. 4:1385–1398. 2004. View Article : Google Scholar : PubMed/NCBI

5 

Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P and Lizard-Nacol S: Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat. 61:13–20. 2000. View Article : Google Scholar : PubMed/NCBI

6 

Mairinger S, Erker T, Muller M and Langer O: PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab. 12:774–792. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N and Piana L: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst. 86:1539–1545. 1994. View Article : Google Scholar : PubMed/NCBI

8 

Vaclavikova R, Nordgard SH, Alnaes GI, Hubackova M, Kubala E, Kodet R, Mrhalova M, Novotny J, Gut I, Kristensen VN and Soucek P: Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): Effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics. 18:263–273. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, Brynychova V, Mrhalova M, Kodet R, Rob L, Pluta M, Gut I, Soucek P and Vaclavikova R: The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics. 102:96–101. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, Law MH, Henderson MJ, Russell AJ, Hedditch EL, Emmanuel C, et al: ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the ovarian cancer association consortium and the cancer genome atlas. Gynecol Oncol. 131:8–14. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Lili X and Xiaoyu T: Expression of PKCα, PKCε, and P-gp in epithelial ovarian carcinoma and the clinical significance. Eur J Gynaecol Oncol. 36:181–185. 2015.PubMed/NCBI

12 

Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G and Nooter K: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res. 9:827–836. 2003.PubMed/NCBI

13 

Chintamani, Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A and Kulshreshtha P: Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study. World J Surg Oncol. 3:612005. View Article : Google Scholar : PubMed/NCBI

14 

Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M and Lage H: Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 7:R862–R870. 2005. View Article : Google Scholar : PubMed/NCBI

15 

Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M and Yu H: Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol Res. 16:395–403. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Tabolacci E and Chiurazzi P: Epigenetics, fragile X syndrome and transcriptional therapy. Am J Med Genet A 161A. 2797–2808. 2013. View Article : Google Scholar

18 

O'Hagan HM, Mohammad HP and Baylin SB: Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 4:e10001552008. View Article : Google Scholar : PubMed/NCBI

19 

Tabish AM, Poels K, Hoet P and Godderis L: Epigenetic factors in cancer risk: Effect of chemical carcinogens on global DNA methylation patternin human TK6 cells. PLoS One. 7:e346742012. View Article : Google Scholar : PubMed/NCBI

20 

Muggerud AA, Rønneberg JA, Wärnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Børresen-Dale AL, Kristensen VN, et al: Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 12:R32010. View Article : Google Scholar : PubMed/NCBI

21 

Dejeux E, Rønneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Børresen-Dale AL, Lønning PE, Kristensen VN and Tost J: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer. 9:682010. View Article : Google Scholar : PubMed/NCBI

22 

Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lønning PE, Solvang H, Børresen-Dale AL, Tost J and Kristensen VN: Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 13:4562013. View Article : Google Scholar : PubMed/NCBI

23 

Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P and Ralhan R: CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem. 43:373–379. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Sharma G, Mirza S, Parshad R, Gupta SD and Ralhan R: DNA methylation of circulating DNA: A marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol. 33:1837–1843. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, et al: CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 64:5956–5962. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Vaclavikova R, Ehrlichova M, Hlavata I, Pecha V, Kozevnikovova R, Trnkova M, Adamek J, Edvardsen H, Kristensen VN, Gut I and Soucek P: Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis. Clin Chem Lab Med. 50:1999–2007. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J and Kristensen VN: DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. Clin Cancer Res. 20:6357–6366. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA and Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 2:811–814. 1996. View Article : Google Scholar : PubMed/NCBI

29 

Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Børresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI

30 

Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G and Lønning PE: TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res. 9:5582–5588. 2003.PubMed/NCBI

31 

Brynychová V, Hlaváč V, Ehrlichová M, Václavíková R, Pecha V, Trnková M, Wald M, Mrhalová M, Kubáčková K, Pikus T, et al: Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. Future Oncol. 9:427–438. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Elsnerova K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, Gut I, Rob L, Skapa P, Hruda M, Bartakova A, Bouda J, et al: Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma. Oncol Rep. 35:2159–2170. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Li LC and Dahiya R: MethPrimer: Designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Tost J and Gut IG: DNA methylation analysis by pyrosequencing. Nat Protoc. 2:2265–2275. 2007. View Article : Google Scholar : PubMed/NCBI

35 

Soucek P, Anzenbacher P, Skoumalová I and Dvorák M: Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells. 23:1417–1422. 2005. View Article : Google Scholar : PubMed/NCBI

36 

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al: The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI

37 

Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC cancer staging manual. 8th. Springer; Cham, Switzerland: 2017, View Article : Google Scholar

38 

Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 370:153–164. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Václavíková R, Boumendjel A, Ehrlichová M, Kovár J and Gut I: Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport? Bioorg Med Chem. 14:4519–4525. 2006.

40 

Němcová-Fürstová V, Kopperová D, Balušíková K, Ehrlichová M, Brynychová V, Václavíková R, Daniel P, Souček P and Kovář J: Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol Appl Pharmacol. 310:215–228. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2019
Volume 42 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Vaclavikova, R., Klajic, J., Brynychova, V., Elsnerova, K., Alnaes, G.I., Tost, J. ... Soucek, P. (2019). Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma. Oncology Reports, 42, 763-774. https://doi.org/10.3892/or.2019.7186
MLA
Vaclavikova, R., Klajic, J., Brynychova, V., Elsnerova, K., Alnaes, G. I., Tost, J., Kristensen, V. N., Rob, L., Kodet, R., Skapa, P., Mrhalova, M., Soucek, P."Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma". Oncology Reports 42.2 (2019): 763-774.
Chicago
Vaclavikova, R., Klajic, J., Brynychova, V., Elsnerova, K., Alnaes, G. I., Tost, J., Kristensen, V. N., Rob, L., Kodet, R., Skapa, P., Mrhalova, M., Soucek, P."Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma". Oncology Reports 42, no. 2 (2019): 763-774. https://doi.org/10.3892/or.2019.7186